Goldman Sachs Group Inc Century Therapeutics, Inc. Transaction History
Goldman Sachs Group Inc
- $580 Billion
- Q2 2024
A detailed history of Goldman Sachs Group Inc transactions in Century Therapeutics, Inc. stock. As of the latest transaction made, Goldman Sachs Group Inc holds 70,806 shares of IPSC stock, worth $81,426. This represents 0.0% of its overall portfolio holdings.
Number of Shares
70,806
Previous 39,283
80.25%
Holding current value
$81,426
Previous $164,000
9.76%
% of portfolio
0.0%
Previous 0.0%
Shares
17 transactions
Others Institutions Holding IPSC
# of Institutions
62Shares Held
37MCall Options Held
7KPut Options Held
300-
Bain Capital Life Sciences Investors, LLC Boston, MA5.41MShares$6.22 Million2.82% of portfolio
-
Vr Adviser, LLC New York, NY5.39MShares$6.2 Million1.51% of portfolio
-
Casdin Capital, LLC New York, NY5.19MShares$5.97 Million1.14% of portfolio
-
Boxer Capital, LLC San Diego, CA4.9MShares$5.64 Million0.69% of portfolio
-
Black Rock Inc. New York, NY2.9MShares$3.33 Million0.0% of portfolio
About Century Therapeutics, Inc.
- Ticker IPSC
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 58,881,800
- Market Cap $67.7M
- Description
- Century Therapeutics, Inc., a biotechnology company, develops transformative allogeneic cell therapies for the treatment of solid tumor and hematological malignancies. The company's lead product candidate is CNTY-101, an allogeneic, induced pluripotent stem cells (iPSCs)-derived chimeric antigen receptors (CAR)-iNK cell therapy targeting CD19 fo...